Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study
Year: 2016
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Dickran Kazandjian, Neha S Korde, Mark Roschewski, Sham Mailankody, Candis Morrison, Elisabet E. Manasanch, Mary L Kwok, Nishant Tageja, Manisha Bhutani, Adriana Zingone, Rene Costello, Yong Zhang, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, Katherine R. Calvo, Raul C Braylan, Constance M. Yuan, Maryalice Stetler-Stevenson, Diane C. Arthur, Liza Lindenberg, Karen A. Kurdziel, Peter Choyke, Seth M. Steinberg, William Figg, Wyndham H. Wilson, Ola Landgren
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Walter Reed National Military Medical Center, Wheeling Hospital, Carolinas Healthcare System, Levine Cancer Institute, National Institutes of Health Clinical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2610048904